Abstract | BACKGROUND: Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization. OBJECTIVES: METHODS: Nineteen patients were treated with thalidomide for 24 months starting with 200 mg/d for first 2 weeks, followed by 100 mg/d for 11 weeks and a maintenance dose of 100mg on alternate days for 35 weeks, and a gradual scaling down until therapy interruption. Criteria of efficacy were: skin score, serum ACE levels (s-ACE), chest X-ray (CXR), lung function tests (LFTs), and diffusing lung capacity for CO (DLCO). The skin score was computed as arithmetic sum of seven score parameters (min: 0, max: 28). RESULTS: Skin score significantly decreased (P<0.001). Lower skin scores occurred after 3 and 6 months (P<0.05). s-ACE levels decreased over time at the third month (P<0.001). CXR assessed by radiological stage significantly improved during the first 6 months (P<0.001). DLCO showed a continuous trend of improvement. Minor side effects that have forced the suspension of the drug were drowsiness/sedation (74%), constipation (68%), and weight gain (53%). Deep vein thrombosis of the lower limbs occurred in one patient (who did not drop out the study). Eight patients (42%) abandoned thalidomide for axonal sensitive peripheral neuropathy (PN) between the ninth and the 24th month of treatment. CONCLUSIONS:
|
Authors | P Fazzi, E Manni, R Cristofani, G Cei, S Piazza, R Calabrese, A Antonelli, G Siciliano, P Barachini, A Carpi |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 66
Issue 4
Pg. 300-7
(Jun 2012)
ISSN: 1950-6007 [Electronic] France |
PMID | 22494798
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2012 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Thalidomide
|
Topics |
- Adult
- Aged
- Contraindications
- Dose-Response Relationship, Drug
- Drug Resistance
- Feasibility Studies
- Female
- Follow-Up Studies
- Glucocorticoids
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Sarcoidosis
(drug therapy, pathology)
- Sarcoidosis, Pulmonary
(drug therapy, pathology)
- Skin Diseases
(drug therapy, pathology)
- Thalidomide
(administration & dosage, adverse effects, therapeutic use)
- Time Factors
- Treatment Outcome
|